|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.25 SEK | +0.92% |
|
+12.83% | -26.44% |
| May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Genovis AB (publ.) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 40.06 million compared to SEK 71.28 million a year ago. Revenue was SEK 42.84 million compared to SEK 72.36 million a year ago.
Net income was SEK 12.74 million compared to SEK 43.56 million a year ago. Basic earnings per share from continuing operations was SEK 0.19 compared to SEK 0.67 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -26.44% | 238M | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +6.11% | 5.72B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B |
GENOVIS AB 
